Abstract
Background/Aim
Elevated serum interleukin-16 (IL-16) levels have been reported in gastric cancer (GC) tissues; however, the role of IL-16 genotypes in GC susceptibility remains largely unexplored. This study aimed to investigate the contribution of IL-16 genotypes to GC susceptibility and to assess their interactions with smoking, alcohol drinking, and Helicobacter pylori (H. pylori) infection.
Materials and Methods
Polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) methodology was employed to determine IL-16 rs4778889, rs11556218, and rs4072111 genotypic characteristics in 161 patients with GC and 483 controls.
Results
Significant differences were observed in the distribution of genotypic (p=0.0009) and allelic (p=0.0002) frequencies of IL-16 rs11556218 among cases and controls. Specifically, the frequencies of TG and GG genotypes of IL-16 rs11556218 were 37.3% and 6.8% among patients with GC, respectively, which were higher than those among the controls (26.7% and 2.7%). In contrast, no significant differences were found concerning IL-16 rs4778889 or rs4072111. Notably, individuals with IL-16 rs11556218 TT genotypes exhibited significant protective effects against GC when exposed to risk factors, such as smoking, alcohol drinking, and H. pylori infection.
Conclusion
IL-16 rs11556218 T allele was associated with reduced susceptibility to GC. Furthermore, carriers of the TT genotype showed protection against GC risk factors, including smoking, alcohol drinking, and H. pylori infection. These findings provide valuable insights into the potential role of IL-16 genotypes in GC development and their interactions with lifestyle and infectious factors.
Keywords: Gastric cancer, genotype, interleukin-16, single nucleotide polymorphism, Taiwan
In spite of its declining trends in incidence and mortality rates, gastric cancer (GC) remains the fifth most common cancer worldwide (1,2). Approximately two-thirds of GC cases occur in developing countries, with up to three-quarters of cases concentrated in Asia (3,4). The detailed mechanisms of gastric carcinogenesis remain largely unknown but are believed to be complex. Generally, Asian countries exhibit higher incidence and mortality rates compared to other global regions, with over 60% of GC cases recently reported in Eastern Asia (5). Common risk factors for GC include Helicobacter pylori (H. pylori) infection, genetic alterations, dietary habits, smoking behaviors, and heavy alcohol consumption (6,7). However, the role of inherited genetic variations in determining individual susceptibility to GC remains largely unrevealed (8-11). In recent decades, with the decoding of the human genome, numerous studies have been conducted to investigate the associations of specific genes with the risk of GC (10,12-16).
Interleukin-16 (IL-16) is a cytokine known as lymphocyte chemoattractant factor (17). It is encoded by the IL-16 gene located on chromosome 15q26.3 and consists of 631 amino acids. Caspase 3 cleaves IL-16 into its active form, comprising the C-terminal 121 amino acids (18-20). When IL-16 binds to the CD4 protein, it activates CD4+ T cells, monocytes, macrophages, eosinophils, and dendritic cells, leading to the secretion of inflammatory cytokines, such as IL-1β (21), TNF-α, and IL-15 (22). Interestingly, elevated IL-16 has been observed in various types of cancer tissues both in vitro and in vivo (23-28), including GC (29). In 2017, elevated serum IL-16 levels were found in patients with GC compared to healthy controls, and these elevated levels were significantly associated with tumor recurrence and poor prognosis (30). Furthermore, a genome-wide association study reported that IL-16 genotype might serve as a practical marker for prostate cancer prediction (31). In 2009, another study indicated that the IL-16 rs11556218 T/G variant was significantly associated with the risk of colorectal cancer and GC in both male and female patients (29). In the same study, female carriers of the T allele at IL-16 rs4072111 had a lower risk of developing colorectal cancer and GC compared to those carrying the C allele (29). Additionally, in 2013, IL-16 rs4778889 CC and rs11556218 GG genotypes were found to be associated with an increased GC risk in another Chinese population (32). However, IL-16 rs4072111 or rs1131445 genotypes were not associated with GC risk in the same study (32). In 2016, IL-16 rs4778889 were found not to associate with GC risk in another Chinese population (33). On the contrary, in the same year, the rs1131445 and rs4072111 variants of IL-16 were significantly associated with an increased risk of GC in an Iranian population (34).
As shown above, despite the significance of serum IL-16 as a potential marker in GC pathogenesis, there have been limited investigations into the association between IL-16 genotypes and GC. In light of these observations, this study aimed to evaluate whether the rs4778889, rs11556218, and rs4072111 polymorphisms of IL-16 are associated with the individual risk of GC in a representative Taiwanese population. Additionally, we also examined the combined effect of smoking, alcohol consumption, H. pylori infection status, and IL-16 genotypes on GC risk.
Materials and Methods
Investigated GC controls and cases. A total of 161 patients diagnosed with GC were recruited from the outpatient clinics of General Surgery at the China Medical University Hospital (CMUH), as previously reported (14,15,35). Briefly, all participants voluntarily provided peripheral blood samples. For comparison, 483 non-cancer healthy individuals matched for age and sex were selected from the Health Examination Cohort of CMUH. The demographic characteristics, including age, sex, body mass index (BMI), smoking, alcohol drinking, H. pylori infection status, and histological types, are presented in Table I.
Table I. Selected characteristics of the control and gastric cancer groups.
ap-value based on χ2 test; bDrunk more than twice weekly or more than 100 ml per day for at least half year; cMore than 1 pack per day for at least half year. BMI: Body mass index. *Statistically significant.
IL-16 genotyping conditions. Genomic DNA from peripheral blood leukocytes of each patient with GC and control subject was extracted using the QIAamp Blood Mini Kit (Blossom, Taipei, Taiwan, ROC) (36,37). Subsequently, the DNA samples were subjected to standard polymerase chain reaction (PCR) procedures, as previously described in our publications (38,39). The primer sequences, restriction endonucleases (New England BioLabs, Ipswich, MA, USA), and PCR products after enzyme digestion for IL-16 genotyping are summarized in Table II. Agarose gel (3%) was freshly prepared using 0.5X Tris-Borate-EDTA (TBE) buffer for electrophoresis under conditions of 100 Volts for 25 min. For the genotyping analysis, three researchers, as mentioned in the Acknowledgments, conducted the analysis independently and blindly. The results were found to be 100% consistent among the different researchers.
Table II. Sequences of the primers, restriction endonucleases, and adduct fragments for IL-16 rs4778889, rs11556218, and rs4072111 polymorphic genotyping in gastric cancer.
Statistical analyses. One hundred and sixty-one GC cases and four hundred and eighty-three controls, all of whom had complete genotypic and demographic information, were included in the final analysis. The Student’s t-test was employed to assess the difference in age between the case and control groups. For comparisons of the distribution of IL-16 genotypes between the case and control groups, the Pearson’s Chi-square test was used. Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated to estimate the associations between IL-16 genotypes and GC risk. Statistical significance was considered at p<0.05 for any comparison outcome.
Results
Table I presents the demographic characteristics of the 644 participants, comprising 161 patients with GC and 483 non-cancer healthy controls, who were included in this study. Age and sex were matched, and no significant differences were observed in age distribution (p=0.3519) or sex distribution (p=1.0000) between the two groups. However, significant differences were found in the distributions of smoking (p<0.0001), alcohol drinking (p<0.0001), and H. pylori infection status (p<0.0001) between the GC and non-cancer control groups, indicating that these factors may act as risk factors for GC in the Taiwanese population. In terms of the pathological tumor location, the majority of patients with GC (60.9%) had tumors located in the upper (14.2%), middle (42.9%), and lower (42.9%) regions, as shown in Table I.
Table III presents the distribution of genotypic frequencies for rs4778889, rs11556218, and rs4072111 in IL-16 among all study participants. First, all genotypic frequencies for the three SNPs were in agreement with the Hardy-Weinberg equilibrium in the control group (all p>0.05). Second, regarding IL-16 rs4778889, there was no significant difference observed among the genotypes (p for trend=0.7674). Specifically, the frequencies of the IL-16 rs4778889 heterozygous variant CT and homozygous variant CC were 26.1% and 3.7% among the GC patients, respectively, which were not significantly different from those among the non-cancer controls (28.8% and 3.1%, OR=0.88 and 1.16, 95%CI=0.59-1.32 and 0.44-3.07, p=0.6053 and 0.9582, respectively) (Table III, top panel). Third, there was a significant difference in the distribution of IL-16 rs11556218 genotypic frequencies between patients with GC and non-cancer controls (p for trend=0.0008) (Table III, middle panel). Specifically, the frequency of the IL-16 rs11556218 heterozygous variant TG and homozygous variant GG among patients with GC were 37.3% and 6.8%, respectively, significantly higher than those among the non-cancer controls (26.7% and 2.7%, OR=1.76 and 3.21, 95%CI=1.20-2.59 and 1.39-7.40, p=0.0050 and 0.0090, respectively). When the TG+GG variants at IL-16 rs11556218 were combined, the elevated risk for GC still existed in these combined genotypes compared with the wild-type TT genotype (OR=1.89, 95%CI=1.31-2.74, p=0.0008) (Table III, middle panel). Finally, for IL-16 rs4072111, no significant difference was observed among the genotypes (p for trend=0.6595). Specifically, the frequencies of the IL-16 rs4072111 heterozygous variant CT and homozygous variant TT among GC patients with GC were 28.6% and 4.3%, respectively, which were not significantly different from those among the non-cancer controls (28.2% and 3.3%, OR=1.04 and 1.34, 95%CI=0.70-1.54 and 0.54-3.35, p=0.9404 and 0.7015, respectively) (Table III, bottom panel).
Table III. Distribution of IL-16 rs4778889, rs11556218, and rs4072111 genotypes among the 161 gastric cancer cases and 483 controls.
aBased on Chi-square with Yate’s correction test; ptrend: p-Value for trend analysis; pHWE: p-Value for Hardy-Weinberg Equilibrium; *Statistically significant.
The allelic frequencies of IL-16 rs4778889, rs11556218, and rs4072111 were analyzed to further validate the findings presented in Table III. Consistent with the conclusive results in Table III, the variant G allele at IL-16 rs11556218 was found to be significantly associated with an elevated risk of GC when compared with the wild-type allele T (OR=1.79, 95%CI=1.32-2.42, p=0.0002) (Table IV). The frequencies of the T and G alleles of IL-16 rs11556218 were 74.5% and 25.5% among patients with GC, respectively, whereas they were 84.0% and 16.0% among non-cancer controls (Table IV). On the other hand, neither the variant C allele of IL-16 rs4778889 nor the variant T allele of IL-16 rs4072111 showed any association with altered GC risk (Table IV). The allelic frequencies of IL-16 rs4778889 and rs4072111 did not differ significantly between patients with GC and non-cancer controls (Table IV).
Table IV. Distributions of IL-16 rs4778889, rs11556218, and rs4072111 allelic frequencies among the gastric cancer cases and controls.
aBased on Chi-square with Yate’s correction test; *Statistically significant.
As GC is one of the smoking-related types of cancer, we conducted further analysis to investigate the potential interaction between the genotype of IL-16 rs11556218 and personal smoking behavior within the study population. The results indicated that non-smokers carrying variant TG or GG genotypes at IL-16 rs11556218 did not exhibit any altered risk for GC (OR=0.72, 95%CI=0.46-1.14, p=0.1974) (Table V). In contrast, ever smokers who carried the TG or GG genotypes at IL-16 rs11556218 were found to have a significantly elevated risk of GC (OR=4.74, 95%CI=2.47-9.09, p=0.0001) (Table V). However, forever smokers carrying the TT genotype at IL-16 rs11556218, no significant difference in risk was observed between the patients with GC and non-cancer control groups (OR=1.35, 95%CI=0.75-2.42, p=0.3993) (Table V). No joint effect was found between IL-16 rs4778889 or rs4072111 genotypes and smoking on the determination of GC risk (data not shown).
Table V. Association of IL-16 rs11556218 genotype and cigarette consumption for gastric cancer risk.
CI: Confidence interval; ap-Value based on Chi-square test. *Statistically significant.
In Table I, the data also indicated that alcohol drinking may be a significant environmental risk factor for GC. Hence, we further explored the genetic-environment interaction between IL-16 rs11556218 and alcohol drinking behavior in relation to the risk of GC (Table VI). Among individuals who were non-alcohol drinkers, carriers of the variant TG or GG genotype at IL-16 rs11556218 did not show any altered risk of GC (OR=0.70, 95%CI=0.45-1.09, p=0.1471) (Table VI). Conversely, among alcohol drinkers who carried the variant TG or GG genotypes at IL-16 rs11556218, there was a significantly elevated risk of GC (OR=3.42, 95%CI=1.81-6.49, p=0.0002) (Table VI). However, forever alcohol drinkers carrying the TT genotype at IL-16 rs11556218, no significant difference in risk was observed between the GC patient and non-cancer control groups (OR=0.94, 95%CI=0.53-1.67, p=0.9447) (Table VI). No joint effect was found between IL-16 rs4778889 or rs4072111 genotypes and alcohol consumption on the determination of GC risk (data not shown).
Table VI. Association of IL-16 rs11556218 genotype and alcohol consumption for gastric cancer risk.
CI: Confidence interval; ap-Value based on Chi-square test. *Statistically significant.
The most intriguing aspect of our findings is the combined effects of H. pylori infection status and IL-16 rs11556218 genotypes on GC risk. Among non-infected individuals, the presence of IL-16 rs11556218 genotype was not associated with any significant alteration in the risk of GC (OR=1.68, 95%CI=0.82-3.47, p=0.2052). However, in individuals with H. pylori infection, there was a remarkable increase in the risk of GC among those carrying the variant TG or GG genotypes at IL-16 rs11556218 (OR=7.90, 95%CI=3.83-16.31, p<0.0001). Notably, H. pylori-infected individuals with the TT genotype of IL-16 rs11556218 exhibited a lower level of elevated GC risk compared to those with the TG or GG genotypes (OR=2.50, 95%CI=1.23-5.04, p=0.0223). No joint effect was observed between IL-16 rs4778889 or rs4072111 genotypes and alcohol consumption in the determination of GC risk (data not shown).
Discussion
In the current study, we examined the association between IL-16 genotypes and the risk of GC in a Taiwanese population, consisting of 161 patients with GC and 483 non-cancer healthy controls (Table I). The genotyping results revealed that carriers of the IL-16 rs11556218 T allele had a reduced risk of GC (Table III and Table IV). Specifically, the variant TG and GG genotypes of IL-16 rs11556218 served as diagnostic biomarkers for predicting an elevated risk of GC in Taiwan. Moreover, we found compelling evidence indicating that the variant genotypes of IL-16 rs11556218 were linked to an increased GC risk among subgroups of smokers, alcohol drinkers, and individuals infected with H. pylori (Table V, Table VI, and Table VII). Interestingly, for the subgroups carrying the IL-16 rs11556218 TT wild-type genotype, the risk of GC was significantly lower compared to those carrying the IL-16 rs11556218 variant TG and GG genotypes (Table V, Table VI, and Table VII).
Table VII. Association of IL-16 rs11556218 genotype and H. pylori infection for gastric cancer risk.
CI: Confidence interval; ap-Value based on Chi-square test. *Statistically significant.
Among the three polymorphic sites, rs11556218 is a missense variant responsible for encoding amino acids. The wild-type T allele encodes Asn, while the variant G allele encodes Lys. In a study conducted by Gao and colleagues in 2009, it was reported that the expression level of IL-16 was higher in patients with colorectal cancer and GC (29). However, to date, there is no conclusive evidence regarding the genotype-phenotype correlation, and the exact role of IL-16 in GC etiology remains unclear. Furthermore, we have not measured the serum expression levels of IL-16 in patients with GC and non-cancer controls. Determining the expression level of IL-16 could provide valuable insights into understanding the role of IL-16 in GC carcinogenesis.
In the present study, we identified the TG and GG genotypes of IL-16 rs11556218 as potential diagnostic biomarkers for GC in Taiwan (Table III and Table IV). Our findings align with the report by Zhang et al. (32), which also showed a positive association between IL-16 rs11556218 genotypes and increased GC risk. Notably, similar associations with elevated risk have been observed in several other types of cancer, including lung cancer (39), colorectal cancer (29), HBV-related hepatocellular carcinoma (40), and nasopharyngeal carcinoma (29).
In contrast to the findings of Zhang et al. (32), our study showed a negative association between the C allele of IL-16 rs4778889 and GC risk (Table III and Table IV). This result is in line with the study conducted by Wang in 2016 (33), which also found no significant association. Interestingly, IL-16 rs4778889 genotypes have been reported to be associated with renal cell carcinoma (41). Moreover, a meta-analysis examining the IL-16 genotype and its association with several types of cancer, including renal cell carcinoma, revealed that the C allele at IL-16 rs4778889 significantly correlates with an increased risk of renal cell carcinoma, particularly among Asian ethnicities (42).
The role of the variant T allele of IL-16 rs4072111 in GC risk is still controversial. In 2009, it was suggested to contribute to a decreased risk of GC in a Chinese population (29). However, in 2016, a study reported that the T allele was associated with an elevated risk of GC in an Iranian population (34). In our current study, we found that the T allele of rs4072111 seemed to be neither associated with an elevated nor a decreased risk of GC (Table III and Table IV). This finding is consistent with a report from Zhang et al. who investigated another Chinese population (32). Another polymorphic site, rs1131445, has also been investigated for its contribution to GC risk. However, the results are conflicting, with one study suggesting a positive association (34), whereas another found no association with GC risk (32).
Smoking has been previously reported to positively contribute to GC (43,44). In this study, we further analyzed the interaction between the genotype of IL-16 rs11556218 and cigarette smoking status. The results revealed that the risk of GC was significantly elevated among smokers without TT genotypes of IL-16 rs11556218 (Table V). Conversely, smokers carrying the protective TT genotypes of IL-16 rs11556218 exhibited a non-significant level of GC risk, with the odds ratios (ORs) decreasing from 4.74 to 1.35 (Table V). Similar findings were observed in alcohol drinkers (Table VI). However, the most intriguing finding is the interaction between IL-16 rs11556218 genotype and H. pylori infection status. The data demonstrated that individuals infected with H. pylori carrying IL-16 rs11556218 TT genotype had an extremely high OR (7.90) of GC risk, which was significantly reduced to 2.5 among individuals infected with H. pylori carrying the TT genotype. Unlike smokers or alcohol drinkers, the protective effects of IL-16 rs11556218 TT genotype were not strong enough to mitigate the risk to a non-risk level for individuals infected with H. pylori. These results indicate that IL-16 rs11556218 genotype not only determines personal susceptibility to GC but also regulates the risk for smokers, alcohol drinkers, and those infected with H. pylori with respect to GC. The mechanisms underlying the role of IL-16 in personal immunology are intriguing and warrant further investigation.
In conclusion, this study provides compelling evidence that the variant TG and GG genotypes of IL-16 rs11556218 are associated with an increased risk of GC among Taiwanese individuals, particularly among smokers, alcohol drinkers, and those infected with H. pylori. However, further investigations are warranted to explore the protective role of IL-16 rs11556218. Additionally, conducting more genotyping studies on IL-16 could help to validate our findings and potentially establish IL-16 rs11556218 T allele as a protective marker for GC risk.
Conflicts of Interest
All the Authors declare no conflicts of interest regarding this study.
Authors’ Contributions
Research design: Fu CK, Mong MC, Bau DT; patient and questionnaire summaries: Fu CK, Yang MD, Tzeng HE, Hsia TC, Hsia NY, Chen CP; experimental supervision: Chang WS, Tsai CW; data recognition: Fu CK, Tsai CW, Chen CP; statistical analysis: Mong MC, Tzeng HE, Chen JC; manuscript writing: Chen CP, Bau DT; review & revision: Bau DT, Chang WS, Tsai CW.
Acknowledgements
The Authors are grateful to the Tissue-bank of China Medical University Hospital and doctors/nurses under Prof. Yang’s leadership for their excellent sample collection and technical assistance. The technical assistance from Yu-Ting Chin, Yu-Hsin Lin, and Hou-Yu Shih were extremely helpful. This study was supported by Taichung Armed Forces General Hospital (grand number: TCAFGH-D-110014), Chung Shan Medical University Hospital (grand number: CSH-2023-A-002) and Asia University and China Medical University Hospital (grand number: CMU111-ASIA-02 and CMU112-ASIA-03). None of the funders had taken part in the study design, data collection and analysis, decision to publish or preparation of the manuscript.
References
- 1.Han H, Wang Z, Zhao X, Li G, Fu Y, Wang Z, Wang H. Global scientific trends in laparoscopy and gastric cancer in the 21st century: A bibliometric and visual mapping analysis. Front Oncol. 2023;13:1136834. doi: 10.3389/fonc.2023.1136834. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Yan C, Shan F, Ying X, Li Z. Global burden prediction of gastric cancer during demographic transition from 2020 to 2040. Chin Med J (Engl) 2023;136(4):397–406. doi: 10.1097/CM9.0000000000002626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Collatuzzo G, Santucci C, Malvezzi M, La Vecchia C, Boffetta P, Negri E. Trends in gastric cancer mortality 1990-2019 in 36 countries worldwide, with predictions to 2025, and incidence, overall and by subtype. Cancer Med. 2023;12(8):9912–9925. doi: 10.1002/cam4.5685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Li J, Kuang XH, Zhang Y, Hu DM, Liu K. Global burden of gastric cancer in adolescents and young adults: estimates from GLOBOCAN 2020. Public Health. 2022;210:58–64. doi: 10.1016/j.puhe.2022.06.010. [DOI] [PubMed] [Google Scholar]
- 5.Sekiguchi M, Oda I, Matsuda T, Saito Y. Epidemiological trends and future perspectives of gastric cancer in Eastern Asia. Digestion. 2022;103(1):22–28. doi: 10.1159/000518483. [DOI] [PubMed] [Google Scholar]
- 6.Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, Pu J, Lv J. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452–2468. doi: 10.3748/wjg.v29.i16.2452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338–349. doi: 10.1038/s41571-023-00747-0. [DOI] [PubMed] [Google Scholar]
- 8.Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333(1):32–41. doi: 10.1056/NEJM199507063330107. [DOI] [PubMed] [Google Scholar]
- 9.Lin CH, Lin CC, Tsai CW, Chang WS, Yang CW, Bau DT. Association of caveolin-1 genotypes with gastric cancer in Taiwan. Anticancer Res. 2014;34(5):2263–2267. [PubMed] [Google Scholar]
- 10.Kuo WH, Huang CY, Fu CK, Hsieh YH, Liao CH, Hsu CM, Huang YK, Tsai CW, Chang WS, Bau DT. Effects of interleukin-10 polymorphisms and smoking on the risk of gastric cancer in Taiwan. In Vivo. 2014;28(5):967–971. [PubMed] [Google Scholar]
- 11.Kuo HW, Huang CY, Fu CK, Liao CH, Hsieh YH, Hsu CM, Tsai CW, Chang WS, Bau DT. The significant association of CCND1 genotypes with gastric cancer in Taiwan. Anticancer Res. 2014;34(9):4963–4968. [PubMed] [Google Scholar]
- 12.Bau DT, Wang HC, Liu CS, Chang CL, Chiang SY, Wang RF, Tsai CW, Lo YL, Hsiung CA, Lin CC, Huang CY. Single-nucleotide polymorphism of the Exo1 gene: association with gastric cancer susceptibility and interaction with smoking in Taiwan. Chin J Physiol. 2009;52(6):411–418. doi: 10.4077/cjp.2009.amh076. [DOI] [PubMed] [Google Scholar]
- 13.Yang MD, Wang HC, Chang WS, Tsai CW, Bau DT. Genetic polymorphisms of DNA double strand break gene Ku70 and gastric cancer in Taiwan. BMC Cancer. 2011;11:174. doi: 10.1186/1471-2407-11-174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Fu CK, Chang WS, Tsai CW, Wang YC, Yang MD, Hsu HS, Chao CY, Yu CC, Chen JC, Pei JS, Bau DT. The association of MMP9 promoter Rs3918242 genotype with gastric cancer. Anticancer Res. 2021;41(7):3309–3315. doi: 10.21873/anticanres.15118. [DOI] [PubMed] [Google Scholar]
- 15.Fu CK, Chien YC, Chuang HY, Wang YC, Hwang JJ, Yang MD, Yu CC, Chen JC, Chang WS, Bau DT, Tsai CW. The association of MMP7 promoter polymorphisms with gastric cancer. Anticancer Res. 2020;40(2):695–702. doi: 10.21873/anticanres.13999. [DOI] [PubMed] [Google Scholar]
- 16.Ji HX, Chang WS, Tsai CW, Wang JY, Huang NK, Lee AS, Shen MY, Chen WY, Chiang YC, Shih TC, Hsu CM, Bau DT. Contribution of DNA repair xeroderma pigmentosum group D genotype to gastric cancer risk in Taiwan. Anticancer Res. 2015;35(9):4975–4981. [PubMed] [Google Scholar]
- 17.Center DM, Cruikshank W. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol. 1982;128(6):2563–2568. [PubMed] [Google Scholar]
- 18.Baier M, Bannert N, Werner A, Lang K, Kurth R. Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor. Proc Natl Acad Sci U S A. 1997;94(10):5273–5277. doi: 10.1073/pnas.94.10.5273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Drwinga HL, Toji LH, Kim CH, Greene AE, Mulivor RA. NIGMS human/rodent somatic cell hybrid mapping panels 1 and 2. Genomics. 1993;16(2):311–314. doi: 10.1006/geno.1993.1190. [DOI] [PubMed] [Google Scholar]
- 20.Zhang Y, Center DM, Wu DM, Cruikshank WW, Yuan J, Andrews DW, Kornfeld H. Processing and activation of pro-Interleukin-16 by Caspase-3. J Biol Chem. 1998;273(2):1144–1149. doi: 10.1074/jbc.273.2.1144. [DOI] [PubMed] [Google Scholar]
- 21.Mathy NL, Scheuer W, Lanzendörfer M, Honold K, Ambrosius D, Norley S, Kurth R. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology. 2000;100(1):63–69. doi: 10.1046/j.1365-2567.2000.00997.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Zheng Y, Cao KY, Ng SP, Chua DT, Sham JS, Kwong DL, Ng MH, Lu L, Zheng BJ. Complementary activation of peripheral natural killer cell immunity in nasopharyngeal carcinoma. Cancer Sci. 2006;97(9):912–919. doi: 10.1111/j.1349-7006.2006.00252.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother. 2001;55(2):111–116. doi: 10.1016/s0753-3322(00)00023-8. [DOI] [PubMed] [Google Scholar]
- 24.Liebrich M, Guo LH, Schluesener HJ, Schwab JM, Dietz K, Will BE, Meyermann R. Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch Immunol Ther Exp (Warsz) 2007;55(1):41–47. doi: 10.1007/s00005-007-0003-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Koike M, Sekigawa I, Okada M, Matsumoto M, Iida N, Hashimoto H, Oshimi K. Relationship between CD4+/CD8+ T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res. 2002;26(8):705–711. doi: 10.1016/s0145-2126(01)00192-8. [DOI] [PubMed] [Google Scholar]
- 26.Alexandrakis MG, Passam FH, Kyriakou DS, Christophoridou AV, Perisinakis K, Hatzivasili A, Foudoulakis A, Castanas E. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. Am J Hematol. 2004;75(2):101–106. doi: 10.1002/ajh.10444. [DOI] [PubMed] [Google Scholar]
- 27.Passam FH, Sfiridaki A, Pappa C, Kyriakou D, Petreli E, Roussou PA, Alexandrakis MG. Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol. 2007;0(0):070129105256005–???. doi: 10.1111/j.1365-2257.2006.00890.x. [DOI] [PubMed] [Google Scholar]
- 28.Blaschke V, Reich K, Letschert M, Sachse F, Harwix S, Neumann C, Middel P. Expression of the CD4+ cell-specific chemoattractant Interleukin-16 in mycosis fungoides. J Invest Dermatol. 1999;113(4):658–663. doi: 10.1046/j.1523-1747.1999.00717.x. [DOI] [PubMed] [Google Scholar]
- 29.Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H, Zhou B, Sun H, Li Y, Lv ML, Du XJ, Zhang L. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis. 2008;30(2):295–299. doi: 10.1093/carcin/bgn281. [DOI] [PubMed] [Google Scholar]
- 30.Yang H, Han Y, Wu L, Wu C. Diagnostic and prognostic value of serum interleukin-16 in patients with gastric cancer. Mol Med Rep. 2017;16(6):9143–9148. doi: 10.3892/mmr.2017.7688. [DOI] [PubMed] [Google Scholar]
- 31.Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40(3):310–315. doi: 10.1038/ng.91. [DOI] [PubMed] [Google Scholar]
- 32.Zhang T, Wang H. Variants of Interleukin-16 associated with gastric cancer risk. Asian Pac J Cancer Prev. 2013;14(9):5269–5273. doi: 10.7314/apjcp.2013.14.9.5269. [DOI] [PubMed] [Google Scholar]
- 33.Wang YM, Li ZX, Tang FB, Zhang Y, Zhou T, Zhang L, Ma JL, You WC, Pan KF. Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population. Tumour Biol. 2016;37(2):2233–2242. doi: 10.1007/s13277-015-4022-x. [DOI] [PubMed] [Google Scholar]
- 34.Kashfi SMH, Behboudi Farahbakhsh F, Nazemalhosseini Mojarad E, Mashayekhi K, Azimzadeh P, Romani S, Derakhshani S, Malekpour H, Asadzadeh Aghdaei H, Zali MR. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer. Tumour Biol. 2016;37(2):2119–2126. doi: 10.1007/s13277-015-4013-y. [DOI] [PubMed] [Google Scholar]
- 35.Yang MD, Lin KC, Lu MC, Jeng LB, Hsiao CL, Yueh TC, Fu CK, Li HT, Yen ST, Lin CW, Wu CW, Pang SY, Bau DT, Tsai FJ. Contribution of matrix metalloproteinases-1 genotypes to gastric cancer susceptibility in Taiwan. Biomedicine (Taipei) 2017;7(2):10. doi: 10.1051/bmdcn/2017070203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Tsai CW, Shih LC, Chang WS, Hsu CL, He JL, Hsia TC, Wang YC, Gu J, Bau DT. Non-homologous end-joining pathway genotypes significantly associated with nasopharyngeal carcinoma susceptibility. Biomedicines. 2023;11(6):1648. doi: 10.3390/biomedicines11061648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Chang SM, Yang YC, Chen GL, Chen LH, Shen TC, Liu YF, Wang YC, Tsai CW, Hsia TC, Bau DT, Chang WS. The association of DNA Ligase 1 Rs20579 polymorphism with lung cancer risk among Taiwanese. In Vivo. 2023;37(4):1504–1510. doi: 10.21873/invivo.13235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Shih LC, Chang WS, Lee HT, Wang YC, Wang ZH, Chao CY, Yu CC, Lin HY, Shen TC, Kuo CC, Tsai CW, Bau DT. Interaction of Interleukin-16 genotypes with betel quid chewing behavior on oral cancer in Taiwan. In Vivo. 2020;34(4):1759–1764. doi: 10.21873/invivo.11969. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wu MF, Wang YC, Shen TC, Chang WS, Li HT, Liao CH, Gong CL, Wang ZH, Tsai CW, Hsia TC, Bau DT. Significant association of Interleukin-16 genetic variations to Taiwanese lung cancer. In Vivo. 2020;34(3):1117–1123. doi: 10.21873/invivo.11883. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Li S, Deng Y, Chen ZP, Huang S, Liao XC, Lin LW, Li H, Peng T, Qin X, Zhao JM. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infect Genet Evol. 2011;11(8):2083–2088. doi: 10.1016/j.meegid.2011.09.025. [DOI] [PubMed] [Google Scholar]
- 41.Wang Z, Xu Y, Zhu S. Interleukin-16 rs4778889 polymorphism contributes to the development of renal cell cancer in a Chinese population. Int J Clin Exp Pathol. 2015;8(11):15228–15233. [PMC free article] [PubMed] [Google Scholar]
- 42.Zhou T, Li H, Xie WJ, Zhong Z, Zhong H, Lin ZJ. Association of methylenetetrahydrofolate reductase, vitamin D receptor, and Interleukin-16 gene polymorphisms with renal cell carcinoma risk. Technol Cancer Res Treat. 2019;18:1533033819859413. doi: 10.1177/1533033819859413. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Lyons K, Le LC, Pham YT, Borron C, Park JY, Tran CT, Tran TV, Tran HT, Vu KT, Do CD, Pelucchi C, La Vecchia C, Zgibor J, Boffetta P, Luu HN. Gastric cancer: epidemiology, biology, and prevention: a mini review. Eur J Cancer Prev. 2019;28(5):397–412. doi: 10.1097/CEJ.0000000000000480. [DOI] [PubMed] [Google Scholar]
- 44.Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012. doi: 10.3390/ijms21114012. [DOI] [PMC free article] [PubMed] [Google Scholar]